Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) with respiratory failure; data expected in early 2026 Productive initial meeting with the FDA on Auxora in acute pancreatitis (AP); conversations continue, with alignment on a pivotal trial anticipated...
Related Questions
How will the company's earnings guidance be adjusted in light of the clinical updates and expected expenses?
What are the key regulatory milestones expected for Auxora in 2026 and how might they impact the stock?
How does the upcoming pivotal trial design compare to existing data and competitor programs?
What are the financial impacts of the FDA meeting outcomes on CalciMedica's cash runway and future financing needs?
How might the early 2026 data readout influence analyst coverage and price targets?
What are the risks associated with trial enrollment rates and endpoint achievement for Auxora?
How does CalciMedica's current valuation compare to peers developing therapies for AKI and acute pancreatitis?
What potential partnership or licensing opportunities could arise from positive trial results?
How will the Phase 2 KOURAGE trial enrollment progress affect Auxora's timeline and valuation?
What are the potential market size and revenue implications of Auxora for AKI with respiratory failure and acute pancreatitis?